This double-blind, randomized, placebo-controlled, multi-center study will evaluate the
safety and efficacy of dalcetrapib in patients hospitalized for an acute coronary syndrome
(ACS). Treatment will be initiated within 1 week after the ACS. Patients will be randomized
to receive dalcetrapib 600 mg as daily oral doses or matching placebo. The anticipated time
on study treatment is 20 weeks.